Nebenwirkungen · Abilify Maintena
Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection in pre- filled syringe Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection in pre- filled syringe · Abschnitt 4.8 · PDF-Seite 13
HOS-129442 · Präparat HOS-096717
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-28T15:16:00Z · SHA-256 41ea025269b746fee63511b9edbf4ea222d53988b45b27fd317f27f82cafb4fe · Passage 591ce3aa6d6555db7032d0551da929e990b92080da2928085827a75c666ec353 · Zeichen 15273–15587 im Abschnitt